ARCT News and Press, Arcturus Therapeutics Ltd. From 09/26/23

CF Foundation Increases Financial Commitment to ~$25 Million Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines ...

Late-breaking data presented at 9 th ESWI Influenza Conference in Valencia Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious...

2023-09-07 05:35:06 ET Summary Results from phase 2 study using ARCT-810 for the treatment of patients with Ornithine-Transcarbamylase [OTC] deficiency are expected in the coming months. The Ornithine-Transcarbamylase Deficiency market is expected to reach $930.33 million by 2030....

2023-09-05 16:00:00 ET Summary Arcturus Therapeutics specializes in mRNA medicines, targeting infectious diseases and rare disorders using proprietary technologies. Despite a financial dip post-Q2 2023, Arcturus remains financially strong, with significant focus and potential in m...

2023-09-05 10:13:43 ET More on Arcturus, CSL, etc. CSL: Watch Out For Positive Surprises CSL Limited ( OTCQX:CSLLY ) Q4 2023 Earnings Call Transcript CSL Limited 2023 Q4 - Results - Earnings Call Presentation Arcturus Therapeutics Holdings Inc. ( ARCT...

EMA application supported by Phase 3 primary vaccination study demonstrating primary efficacy endpoint was met An additional Phase 3 booster study demonstrating non-inferiority of immune response compared to Comirnaty® and superiority of ARCT-154 in neutralizing antibody response aga...

2023-08-14 10:06:41 ET More on Arcturus Therapeutics Arcturus Therapeutics: A Beacon Of Hope For Rare Diseases Amid The mRNA Race Arcturus down 18% on disappointing Q2 results Arcturus Therapeutics receives FDA fast track status for ARCT-810 Arcturus raised t...

LUNAR-FLU collaboration with CSL Seqirus achieves additional $17.5 million development milestone Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the devel...

2023-08-08 14:39:05 ET Shares of Arcturus Therapeutics (NASDAQ: ARCT) fell more than 18% as of 2:15 p.m. ET on Tuesday. The clinical-stage biotech company announced second-quarter earnings after the markets closed on Monday. The stock is still up more than 52% this year. Arc...

2023-08-08 10:21:19 ET Gainers: Bright Minds Biosciences ( DRUG ) +62% . Bionomics ( BNOX ) +24% . Novo Nordisk ( NVO ) +18% . Quanterix ( QTRX ) +17% . Tilray Brands ( TLRY ) +18% . Losers: Vistagen Therapeutics ( VTGN ...